IQ4I Research published a new report on ‘Neuromodulation Devices Global Market – Forecast to 2029’

Contact Us
Mr. Satish Birudukota
No 41/P4, Industrial Suburb 1st Floor,
3rd Main Road 1st Phase, KIADB Peenya
Karnataka 560058 

IQ4I Research & Consultancy published a new report on “Neuromodulation Devices Global Market – Forecast to 2029”.
1) Neuromodulation Devices Global Market, Based on Product:

? Invasive Neuromodulation Devises
? Spinal Cord Stimulation (SCS)
? Deep Brain Stimulation (DBS)
? Sacral Nerve Stimulation (SNS)
? Vagus Nerve Stimulation (VNS)
? Hypoglossal Nerve Stimulation (HGNS)
? Others
o Gastric Electrical Stimulation (GES)
o Respiratory Electrical Nerve Stimulation (RES)/Phrenic Nerve Stimulation (PNS)
? Non-invasive Neuromodulation Devices
? Transcutaneous Electrical Nerve Stimulation (TENS)
? Neuromuscular Electrical Nerve Stimulation (NMES)
? Others

2) Neuromodulation Devices Global Market, Based on Application:

? Pain Management
? Chronic Pain
? Failed Back Surgery Syndrome (FBSS)
? Others
? Central Nervous System
? Parkinson ’s disease
? Dystonia
? Epilepsy
? Others
o Obsessive Compulsive Disorder
o Depression
o Stroke
o Mood disorders
o Anxiety
o Central Sleep Apnea (CSA)
? Gastroenterology and Urology
? Gastroparesis
? Urinary Incontinence
? Faecal Incontinence
? Obstructive Sleep Apnea (OSA)
? Other Applications
? Obesity
? Heart Failure
? Autoimmune Diseases (Rheumatoid Arthritis, Multiple Sclerosis)
? Respiratory Related Diseases (Diaphragm Pacing)
? Diabetes
? Weaning
3) Neuromodulation Devices Global Market, Based on End-User:

? Hospitals and Ambulatory Surgery Centers
? Clinics and Physiotherapy centers
? Others
? Home care
? Academics and Research Institutes

4) Nuclear Medicine Global Market, Based on Geography:

? North America
? United States
? Rest of North America
? Europe
? Germany
? France
? United Kingdom
? Rest of Europe
? Asia-Pacific
? Japan
? China
? India
? Rest of APAC
? Rest of the World
? Brazil
? Rest of Latin America
? Middle East and Others
According to IQ4I Research, the nuclear medicine global market is estimated to grow at a high single-digit CAGR from 2022 to 2029 to reach $9,569.4 million by 2029. Persistently increasing geriatric population, increasing incidence of chronic pain, Parkinson’s and Alzheimer’s disorders, low approval rate of CNS drugs, favorable reimbursement scenario in major markets, the emergence of neuromodulation as add-on therapy, expansion in emerging markets, rise in the number of clinical studies performed, minimally invasive procedure, reduced use of opioids, targeted pain relief, limited or no side effects of procedures, increased number of hospitals, increase in number of procedures performed, high technological advancements in the field of neuromodulation devices, adoption of patient-centric neuromodulation devices, development of home-care based neuromodulation devices, expansion in their indications, increasing in number of product launches, product approvals by the regulatory authorities, a conducive regulatory environment that promotes the adoption of value-enhanced neuromodulation devices and constant research activities for the development of efficient, user-friendly and safer neuromodulation devices are some of the factors which are propelling the neuromodulation devices market growth.

The neuromodulation devices market is highly consolidated with the top five players occupying major share of the market and the remaining share of the market is occupied by other players. The top players in the market are Abbott Laboratories (U.S.), Axonics Modulation Technologies, Inc. (U.S.), Bioventus (Bioness Inc.) (U.S.), Boston Scientific Corporation (U.S.), Inspire Medical Technologies (U.S.), Laborie Medical Technologies, Inc. (Canada), LivaNova Plc (U.K.), Medtronic Plc (Ireland), Neuropace Inc. (U.S.) and Nevro Corporation (U.S.).
For more details please visit our website or contact:
Mr. Satish Birudukota,
Report link:
Phone: +91-9886722024, 8147030229